Sunshine Biopharma, Inc.
SBFM
$1.40
-$0.02-1.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.72% | -7.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.72% | -7.23% | |||
| Cost of Revenue | -2.97% | -5.09% | |||
| Gross Profit | 25.36% | -11.72% | |||
| SG&A Expenses | 10.96% | -24.37% | |||
| Depreciation & Amortization | 11.88% | -0.92% | |||
| Other Operating Expenses | 2.27% | 1.29% | |||
| Total Operating Expenses | 2.02% | -12.34% | |||
| Operating Income | 23.38% | 36.41% | |||
| Income Before Tax | -62.31% | 46.66% | |||
| Income Tax Expenses | -420.40% | 68.76% | |||
| Earnings from Continuing Operations | -50.09% | 45.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.09% | 45.33% | |||
| EBIT | 23.38% | 36.41% | |||
| EBITDA | 25.24% | 37.59% | |||
| EPS Basic | 9.74% | 56.50% | |||
| Normalized Basic EPS | 54.75% | 57.56% | |||
| EPS Diluted | 9.74% | 56.50% | |||
| Normalized Diluted EPS | 54.75% | 57.56% | |||
| Average Basic Shares Outstanding | 66.32% | 25.67% | |||
| Average Diluted Shares Outstanding | 66.32% | 25.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||